Agenus, Inc. (AGEN) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 43 PAGES: 45

Agenus, Inc. (Agenus), formerly Antigenics, Inc., is a developer of therapeutic vaccines for cancer and infectious diseases. It develops and commercializes technologies and products to treat various forms of cancers and infectious diseases. The company's key technology portfolio includes Saponin Platform and Heat Shock Protein (HSP) Platform. Its business activities include product research and development, regulatory and clinical affairs, manufacturing, corporate finance and development, business development, marketing, intellectual property prosecution and administrative functions.

More Info
									          Agenus, Inc. (AGEN) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH4419FSA                                                                                           Publication Date: APR 2013

          3 Forbes Road                                      Phone              +1 781 6744400                  Revenue          2.8 (million USD)
          Lexington, MA                                      Fax                +1 781 6744200                  Net Profit       -23.28 (million USD)
          02421-7305                                         Website            www.agenusbio.com               Employees        54
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           AGEN [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Agenus, Inc. (Agenus), formerly Antigenics, Inc., is a developer of therapeutic vaccines for cancer and infectious diseases. It
       develops and commercializes technologies and products to treat various forms of cancers and infectious diseases. The
       company's key technology portfolio includes Saponin Platform and Heat Shock Protein (HSP) Platform. Its business activities
       include product research and development, regulatory and clinical affairs, manufacturing, corporate finance and development,
       business development, marketing, intellectual property prosecution and administrative functions.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Agenus, Inc., SWOT Analysis
         Garo H. Armen, Ph.D.                Chairman                                 Strengths                              Weaknesses
         Shalini Sharp                       Director
                                                                                      Intellectual Property                  Product Discontinuation -
         Tom Dechaene                        Director                                                                        Aroplatin
                                                                                      Strong In-house Research
         Wadih Jordan                        Director
                                                                                      Capabilities                           History of Losses
         Brian Corvese                       Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Orphan Drug and Fast Track             Competitive Environment
         Agenus, Inc.                                                                 Designations
                                                                                                                             Uncertain R&D Outcomes
        Share Price (USD) as on 28-Mar-                                  3.89         Market Potential for QS-21
        2013                                                                          Adjuvant
        EPS (USD)                                                       -1.21
        Market Cap (million USD)                                           98        Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        Enterprise Value (million USD)                                   115
        Shares Outstanding (million)                                       25
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 28, 2013         Agenus Reports 2012 Results
                                                                                      Oct 25, 2012         Agenus Reports Q3 2012 Results
                                                                                      Aug 02, 2012         Agenus Reports Q2 2012 Results
                                                                                      Jun 18, 2012         Agenus To Join Russell 3000 Index, Global
                                                                                                           Index And MicroCap Index
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Agenus, Inc. (AGEN) - Financial and Strategic SWOT Analysis                                                                     Reference Code: GDPH4419FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Agenus, Inc. - Key Facts .................................................................................................................................................................... 5
       Agenus, Inc. - Key Employees ........................................................................................................................................................... 6
       Agenus, Inc. - Key Employee Biographies ......................................................................................................................................... 7
       Agenus, Inc. - Major Products and Services....................................................................................................................................... 8
       Agenus, Inc. - Pharmaceutical Pipeline Products Data ...................................................................................................................... 9
          Agenus, Inc., Pipeline Products by Therapy Area........................................................................................................................... 9
          Agenus, Inc., Pipeline Products by Development Phase .............................................................................................................. 10
       Agenus, Inc. - History ....................................................................................................................................................................... 12
       Agenus, Inc. - Company Statement.................................................................................................................................................. 15
       Agenus, Inc. - Locations And Subsidiaries ....................................................................................................................................... 16
          Head Office ................................................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       Agenus, Inc. - Business Description ................................................................................................................................................. 17
       Agenus, Inc. - Corporate Strategy .................................................................................................................................................... 18
       Agenus, Inc. - SWOT Analysis ......................................................................................................................................................... 19
          SWOT Analysis - Overview........................................................................................................................................................... 19
          Agenus, Inc. - Strengths ............................................................................................................................................................... 19
             Strength - Intellectual Property .................................................................................................................................................. 19
             Strength - Strong In-house Research Capabilities .................................................................................................................... 19
          Agenus, Inc. - Weaknesses .......................................................................................................................................................... 19
             Weakness - Product Discontinuation - Aroplatin ....................................................................................................................... 19
             Weakness - History of Losses ................................................................................................................................................... 19
          Agenus, Inc. - Opportunities ......................................................................................................................................................... 20
             Opportunity - Orphan Drug and Fast Track Designations ......................................................................................................... 20
             Opportunity - Market Potential for QS-21 Adjuvant ................................................................................................................... 20
             Opportunity - Market Potential for Oncophage .......................................................................................................................... 20
             Opportunity - Partnerships and Collaborations......................................................................................................................... 20
          Agenus, Inc. - Threats................................................................................................................................................................... 21
             Threat - Competitive Environment ............................................................................................................................................. 21
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 21
             Threat - Tightening of FDA’s Regulatory Oversight ................................................................................................................... 21
       Agenus, Inc. - Key Competitors ........................................................................................................................................................ 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          Agenus, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................................................ 28


Agenus, Inc. (AGEN) - Financial and Strategic SWOT Analysis                                                                                                      Reference Code: GDPH4419FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Agenus, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013........................................................................ 29
       Agenus, Inc., Recent Deals Summary.............................................................................................................................................. 30
       Section 5 – Company’s Recent Developments ................................................................................................................................ 31
          Agenus, Inc., Recent Developments ............................................................................................................................................. 31
             Feb 28, 2013: Agenus Reports 2012 Results............................................................................................................................ 31
             Oct 25, 2012: Agenus Reports Q3 2012 Results ...................................................................................................................... 33
             Aug 02, 2012: Agenus Reports Q2 2012 Results...................................................................................................................... 34
             Jun 18, 2012: Agenus To Join Russell 3000 Index, Global Index And MicroCap Index ...................
								
To top